Pharmacologic treatment options in patients with thrombocytopenia

Seminars in Hematology

Volumn 37, Issue 2 SUPPL. 4, 2000, Pages 11-18

  Demetri, George D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C MPL LIGAND; CYTOKINE; CYTOKINE RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GW 395058; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 3; INTERLEUKIN 6; MILODISTIM; PLATELET DERIVED GROWTH FACTOR; PROMEGAPOIETIN; RECOMBINANT INTERLEUKIN 11; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; STEM CELL FACTOR; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; EDEMA; FATIGUE; HUMAN; HUMAN CELL; MYALGIA; NONHUMAN; PRIMATE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

EID: 0034032481     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0037-1963(00)90048-9     Document Type: Review

References (79)

1. LC Platanias CB Miller R Mick Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients J Clin Oncol 9 1991 2021 2026
2. C Oberhoff B Neri D Amadori Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study Ann Oncol 9 1998 255 260
3. MJ Laughlin G Kirkpatrick N Sabiston Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF Ann Hematol 67 1993 267 276
4. G Heil D Hoelzer MA Sanz A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia Blood 90 1997 4710 4718
5. VM Novotny Prevention and management of platelet transfusion refractoriness Vox Sang 76 1999 1 13
6. RC Friedberg PD Mintz Causes of refractoriness to platelet transfusion Curr Opin Hematol 2 1995 493 498
7. M Contreras Diagnosis and treatment of patients refractory to platelet transfusions Blood Rev 12 1998 215 221
8. CP Engelfriet HW Reesink RH Aster Management of alloimmunized, refractory patients in need of platelet transfusions Vox Sang 73 1997 191 198
9. RK Davda KA Collins CS Kitchens Case report: Fatal Staphylococcus aureus sepsis from single-donor platelet transfusion Am J Med Sci 307 1994 340 341
10. EK Chiu KY Yuen AK Lie A prospective study of symptomatic bacteremia following platelet transfusion and of its management Transfusion 34 1994 950 954
11. LA Chambers MS Kruskall DG Pacini Febrile reactions after platelet transfusion: The effect of single versus multiple donors Transfusion 30 1990 219 221
12. J McCullough The potential impact of platelet growth factors in transfusion medicine Curr Opin Hematol 5 1998 386 390
13. S Kudoh T Sawa N Kurihara Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients. SDZ ILE 964 (IL-3) Study Cancer Chemother Pharmacol 38 1996 S89 S95 (suppl)
14. JL Speyer J Mandeli H Hochster A phase I trial of cyclosphosphamide and carboplatinum combined with interleukin-3 in women with advanced-stage ovarian cancer Gynecol Oncol 56 1995 387 394
15. I Tepler A Elias L Kalish Effect of recombinant human interleukin-3 on haematological recovery from chemotherapy-induced myelosuppression Br J Haematol 87 1994 678 686
16. V D'Hondt P Weynants Y Humblet Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: A placebo-controlled randomized phase Ib study J Clin Oncol 11 1993 2063 2071
17. AC Newland Is interleukin 3 active in anticancer drug-induced thrombocytopenia? Cancer Chemother Pharmacol 38 1996 S83 S88 (suppl)
18. LS Hofstra GB Kristensen PH Willemse Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma J Clin Oncol 16 1998 3335 3344
19. J Nemunaitis FR Appelbaum JW Singer Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation Blood 82 1993 3273 3278
20. S Nand J Sosman JE Godwin A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes Blood 83 1994 357 360
21. J Crawford D Lau R Erwin A phase I trial of recombinant methionyl human stem cell factor (SCF) in patients (pts) with advanced non-small cell lung carcinoma (NSCLC) Proc Am Soc Clin Oncol 12 1993 135 (abstr 338)
22. G Demetri J Costa D Hayes A phase I trial of recombinant methionyl human stem cell factor (SCF) in patients with advanced breast carcinoma pre- and post-chemotherapy (CHEMO) with cyclophosphamide (C) and doxorubicin Proc Am Soc Clin Oncol 12 1993 142 (abstr)
23. T Takahashi R Tsuyuoka Y Ueda Megakaryocyte potentiating activity of IL-1, IL-6 and GM-CSF as evaluated by their action on in vitro human megakaryocytic colonies Br J Haematol 78 1991 480 487
24. RJ Hill MK Warren P Stenberg Stimulation of megakaryocytopoiesis in mice by human recombinant interleukin-6 Blood 77 1991 42 48
25. W Kozak MJ Kluger D Soszynski IL-6 and IL-1 β in fever. Studies using cytokine-deficient (knockout) mice Ann NY Acad Sci 856 1998 33 47
26. RF Mortensen J Shapiro BF Lin Interaction of recombinant IL-1 and recombinant tumor necrosis factor in the induction of mouse acute phase proteins J Immunol 140 1988 2260 2266
27. BF Lin NO Ku K Zahedi IL-1 and IL-6 mediate increased production and synthesis by hepatocytes of acute-phase reactant mouse serum amyloid P-component (SAP) Inflammation 14 1990 297 313
28. RE Banks MA Forbes M Storr The acute phase protein response in patients receiving subcutaneous IL-6 Clin Exp Immunol 102 1995 217 223
29. MS Gordon J Nemunaitis R Hoffman A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia Blood 85 1995 3066 3076
30. JWI Smith DL Longo WG Alvord The effects of treatment with interleukin-1α on platelet recovery after high-dose carboplatin N Engl J Med 328 1993 756 761
31. S Vadhan-Raj AP Kudelka L Garrison Effects of interleukin-1α on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer J Clin Oncol 12 1994 707 714
32. J Rinehart E Hersh B Issell Phase 1 trial of recombinant human interleukin-1β (rhIL-1β), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology, Group Study 8940 Cancer Invest 15 1997 403 410
33. J Nemunaitis M Ross B Meisenberg Phase I study of recombinant human interleukin-1β (rhIL-1β) in patients with bone marrow failure Bone Marrow Transplant 14 1994 583 588
34. V D'Hondt Y Humblet T Guillaume Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: A multicentric placebo-controlled, randomized phase Ib study Blood 85 1995 2347 2353
35. HM Lazarus EF Winton SF Williams Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer Bone Marrow Transplant 15 1995 935 942
36. J Nieken NH Mulder J Buter Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients Blood 86 1995 900 905
37. M Musashi YC Yang SR Paul Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture Proc Natl Acad Sci USA 88 1991 765 769
38. M Teramura S Kobayashi S Hoshino Interleukin-11 enhances human megakaryocytopoiesis in vitro Blood 79 1992 327 331
39. NS Weich A Wang M Fitzgerald Recombinant human interleukin-11 directly promotes megakaryocytopoiesis in vitro Blood 90 1997 3893 3902
40. JP Leonard CM Quinto MK Kozitza Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin Blood 83 1994 1499 1506
41. R Maze T Moritz DA Williams Increased survival and multilineage hematopoietic protection from delayed and severe myelosuppressive effects of a nitrosourea with recombinant interleukin-11 Cancer Res 54 1994 4947 4951
42. A Orazi RJ Cooper J Tong Effects of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow Exp Hematol 24 1996 1289 1297
43. MS Gordon WJ McCaskill-Stevens LA Battiato A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy Blood 87 1996 3615 3624
44. C Isaacs NJ Robert FA Bailey Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin J Clin Oncol 15 1997 3368 3377
45. I Tepler L Elias JW Smith II A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy Blood 87 1996 3607 3614
46. JJ Vredenburgh A Hussein D Fisher A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer Biol Blood Marrow Transplant 4 1998 134 141
47. S Vadhan-Raj NE Papadopoulos MA Burgess Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma J Clin Oncol 12 1994 715 724
48. S Vadhan-Raj HE Broxmeyer M Andreeff In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: A phase I study Blood 86 1995 2098 2105
49. CD Runowicz J Mandeli JL Speyer Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer Am J Obstet Gynecol 174 1996 1151 1159
50. JM Vose JE Anderson PJ Bierman Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy J Clin Oncol 14 1996 520 526
51. MR Bishop JD Jackson B O'Kane-Murphy Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells J Clin Oncol 14 1996 2521 2526
52. JM Vose AN Pandite RA Beveridge Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: Results of a randomized double-blind trial J Clin Oncol 15 1997 1617 1623
53. LL Miller EL Korn DS Stevens Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin Blood 93 1999 3250 3258
54. TJ MacVittie AM Farese F Herodin Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC-55494 and recombinant human granulocyte colony-stimulating factor Blood 87 1996 4129 4135
55. AM Farese F Herodin JP McKearn Acceleration of hematopoietic reconstitution with a synthetic cytokine (SC-55494) after radiation-induced bone marrow aplasia Blood 87 1996 581 591
56. L Farber U Haus G Fuchsel Treatment of prolonged chemotherapy induced severe thrombocytopenia with recombinant human interleukin-3—A report on four cases Anticancer Drugs 8 1997 288 292
57. GJ Veldhuis PH Willemse JH Beijnen Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: A feasibility study Br J Cancer 75 1997 703 709
58. SH Bernstein JP Fay NP Christiansen Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: A phase I/II trial Clin Cancer Res 3 1997 1519 1526
59. H Hochster JL Speyer JP Mandeli A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin chemotherapy in patients with advanced epithelial ovarian cancer Gynecol Oncol 72 1999 292 297
60. FJ de Sauvage PE Hass SD Spencer Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand Nature 369 1994 533 538
61. S Lok K Kaushansky RD Holly Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo Nature 369 1994 565 568
62. DJ Kuter DL Beeler RD Rosenberg The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production Proc Natl Acad Sci USA 91 1994 11104 11108
63. F Wendling E Maraskovsky N Debili cMpl ligand is a humoral regulator of megakaryocytopoiesis Nature 369 1994 571 574
64. TD Bartley J Bogenberger P Hunt Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl Cell 77 1994 1117 1124
65. AL Gurney K Carver-Moore FJ de Sauvage Thrombocytopenia in c-mpl-deficient mice Science 265 1994 1445 1447
66. T Kato K Ogami Y Shimada Purification and characterization of thrombopoietin J Biochem (Tokyo) 118 1995 229 236
67. T Kato K Ogami Y Shimada Erratum J Biochem (Tokyo) 119 1996 208
68. K Kaushansky S Lok RD Holly Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin Nature 369 1994 568 571
69. FJ de Sauvage K Carver-Moore SM Luoh Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin J Exp Med 183 1996 651 656
70. ES Choi MM Hokom JL Chen The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis Br J Haematol 95 1996 227 233
71. RL Basser JE Rasko K Clarke Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuPEG-RHUMGDF) in patients with advanced cancer Lancet 348 1996 1279 1281
72. M Fanucchi J Glaspy J Crawford Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer N Engl J Med 336 1997 404 409
73. C Moskowitz S Nimer J Gabrilove A randomized, double-blind, placebo-controlled, dose finding, efficacy and safety study of PEG-rHuPEG-RHUMGDF (M) in non-Hodgkin's lymphoma (NHL) patients (pts) treated with ice (ifosfamide, carboplatin and etoposide) Proc Am Soc Clin Oncol 17 1998 76a (abstt 295)
74. D Kuter J McCullough J Romo Treatment of platelet (PLT) donors with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuPEG-RHUMGDF) increases circulating PLT counts (CTS) and PLT aphersis yields and increases platelet increments in recipients of PLT transfusions Blood 90 suppl 1 1997 579a abstr 2579
75. J Crawford J Glaspy C Belani A randomized, placebo-controlled, blinded, dose scheduling trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-RHUPEG-RHUMGDF) with filgrastim support in non-small cell lung cancer (NSCLC) patients treated with paclitaxel and carboplatin during multiple cycles of chemotherapy Proc Am Soc Clin Oncol 17 1998 73a (abstr 285)
76. S Vadhan-Raj LJ Murray C Bueso-Ramos Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer Ann Intern Med 126 1997 673 681
77. S Vadhan-Raj C Verschraegen L McGarry Recombinant human thrombopoietin (rhTPO) attenuates high-dose carboplatin (C)-induced thrombocytopenia in patients with gynecologic malignancy Blood 90 suppl 1 1997 580a abstr 2581
78. M de Serres B Ellis JE Dillberger Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man Stem Cells (Dayt) 17 1999 203 209
79. P Lefebvre JN Winter LE Kahn Megakaryocyte ex vivo expansion potential of three hematopoietic sources in serum and serum-free medium J Hematother 8 1999 199 208